home / stock / bct:cc / bct:cc news

BCT:CC News and Press, Briacell Therapeutics Corp. From 11/30/23

Stock Information
Company Name: Briacell Therapeutics Corp.
Stock Symbol: BCT:CC
Market: TSXC
Website: briacell.com
Menu
BCT:CC BCT:CC Quote BCT:CC Short BCT:CC News BCT:CC Articles BCT:CC Message Board
Get BCT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BCT:CC - BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded. Heavily treated patient had 7 prior failed regimens ....
BCT:CC - BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS(TM) IND

BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies Data supports further development of BriaCell’s next generation personalized immunotherapy platform with potent ant...

BCT:CC - Expected Canadian Company Earnings on Thursday, October 26th, 2023

Canadian Critical Minerals Inc. (CCMI:CA) is expected to report for quarter end 2023-08-31 Advantage Energy Ltd. (AAV:CA) is expected to report $0.16 for Q3 2023 Canadian Utilities Limited Class A Non-Voting Shares (CU:CA) is expected to report for Q3 2023 Newmont Corporation (NGT:CA)...

BCT:CC - Expected earnings - BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. (BCT:CA) is expected to report $-0.52 for Q4 2023
BCT:CC - BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...

BCT:CC - October is Breast Cancer Awareness Month - BriaCell is Leading the Fight with its Innovative Technology

According to American Cancer Society Facts and Figures, breast cancer is the most common cancer in the United States with 300,590 expected new cases in 2023 43,700 women and men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of can...

BCT:CC - BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
BCT:CC - BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT(TM) Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast cancer and the latest clinical data of the Bria-IMT™ regimen BriaCell recently rep...

BCT:CC - BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast Cancer

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform canc...

BCT:CC - BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria...
Previous 10 Next 10